The application of immune checkpoint blockade with anti-PD-1 in colonic-derived peritoneal neoplasms is rarely reported, and it remains unclear how PD-1 impacts the prognosis of colonic-derived PA. This evidence concerns the gene PDCD1 and peritoneal neoplasm.